1 The retractions came only a few months after BioMed Central.

At the ultimate end of 2014, BioMed Central and other publishers alerted the international Committee on Publication Ethics to new forms of systematic attempts to control journals’ peer-review procedures. According to a declaration published on COPE’s website in January 2015, these efforts to hijack the scholarly review system were evidently orchestrated by firms that 1st helped authors compose or enhance their scientific articles and then marketed them favorable peer evaluations.4 BioMed Central conducted a thorough investigation of most their recently published content and identified 43 which were published on the basis of reviews from fabricated reviewers. All these articles had been retracted in March 2015.All regulatory areas of the project shall be spearheaded by the professional team at Cato Research, a full-support CRO with over twenty years of encounter in drug development solutions, including CMC, clinical and regulatory strategies, as well as clinical trial support. Douglas Lappi, Principal Investigator and President/CSO of Advanced Targeting Systems.

ADI and CeTeCancer collaborate for research study Radient Pharmaceuticals Corporation , a US-based pharmaceutical company, today it has entered into a collaboration contract through its wholly owned subsidiary AMDL Diagnostics announced, Inc.